IP Library Granted Patent US 8,263,093
Granted Patent B2
US 8,263,093 · App. 13/083,306 · Granted Sep 11, 2012

Methods and compositions for administration of TRPV1 agonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,093
App. No.
13/083,306
Granted
Sep 11, 2012
Kind
B2
Abstract

Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions are also provided.

Claims (13)

1. A liquid formulation for treating neuropathic pain associated with a condition comprising:

about 6% (w/v) to about 20% (w/v) capsaicin; and

a solvent system, the solvent system comprising about 10% (v/v) to about 25% (v/v) oleyl alcohol and the remainder propylene glycol.

2. The liquid formulation of claim 1 comprising about 10% (w/v) capsaicin.

3. The liquid formulation of claim 2 , wherein the solvent system comprises about 90% (v/v) of the liquid formulation.

4. The liquid formulation of claim 1 , wherein the condition is diabetic neuropathy.

5. The liquid formulation of claim 1 , wherein the condition is postherpetic neuralgia.

6. The liquid formulation of claim 1 , wherein the condition is HIV/AIDS.

7. The liquid formulation of claim 1 , wherein the condition is traumatic injury.

8. The liquid formulation of claim 1 , wherein the condition is complex regional pain syndrome.

9. The liquid formulation of claim 1 , wherein the condition is trigeminal neuralgia.

10. The liquid formulation of claim 1 , wherein the condition is erythromelalgia.

11. The liquid formulation of claim 1 , wherein the condition is phantom pain.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2019
From: GRÜNENTHAL GMBH
To: GRT US HOLDING, INC.
Reel/Frame 050065/0195 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2019
From: ACORDA THERAPEUTICS, INC.
To: GRÜNENTHAL GMBH
Reel/Frame 049260/0707 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2013
From: NEUROGESX, INC.
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 031775/0168 →
ASSIGNMENT AND RELEASE OF SECURITY INTEREST Recorded Jul 10, 2013
From: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
To: NEUROGESX, INC.
Reel/Frame 030777/0782 →
SECURITY AGREEMENT Recorded Nov 13, 2012
From: NEUROGESX, INC.
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 029291/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2011
From: MUHAMMAD, NAWEED; JAMIESON, GENE C.; BLEY, KEITH R.; CHANDA, SANJAY
To: NEUROGESX, INC.
Reel/Frame 026170/0993 →